

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Tuesday, March 7, 2017

7:00 a.m. – 8:00 a.m.

Palm Ballroom Foyer

Sign-in and Continental Breakfast

8:00 a.m. – 8:15 a.m.

Palm A/D

Opening of Steering Committee Meeting

Joshua LaBaer, M.D., Ph.D. Arizona State University

8:15 a.m. – 8:20 a.m.

Palm A/D

Approval of October, 2016 EDRN Steering Committee Meeting Minutes

Joshua LaBaer, M.D., Ph.D., Arizona State University

8:20 a.m. – 9:00 a.m.

Palm A/D

State of the EDRN

Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

9:00 a.m. – 9:30 a.m.

Palm A/D

Compact Source of Intense X-rays for Biomedical Applications

William Graves, Ph.D., Arizona State University

9:30 a.m. – 10:00 a.m.

Palm A/D

Bioinformatics Resources for the EDRN

Guoping Zhao, Ph.D., Shanghai Institutes for Biological Sciences

10:00 a.m. – 10:20 a.m.

(Palm Ballroom Foyer)

Break

10:20 a.m. – 11:00 a.m.

Palm A/D

Model EDRN Team Projects

Session Moderator: Matt Young, Ph.D., National Cancer Institute

10:20 a.m. – 10:40 a.m.

Designing Productive Collaborative Team Projects: The TNBC Experience

Karen Anderson, M.D., Ph.D., Arizona State University/The Biodesign Institute

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Tuesday March 7, 2017 (Continued)

Model EDRN Team Projects Continued

10:40 a.m. – 11:00 a.m.
Palm A/D

EDRN and DECAMP Lung Cancer Cohorts
Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center

11:00 a.m. – 12:00 p.m.
Palm A/D

Model Projects Supported with CORE Funds
Session Moderator: Karl Krueger, Ph.D., National Cancer Institute

11:00 a.m. – 11:30 a.m.

Prostate Cancer Biomarker Validation Project
Martin Sanda, M.D., Emory University

11:30 a.m. – 12:00 p.m.

Capacity/Resource Building Project for Pancreatic Cancer Supported by CORE Funds

- Randall Brand, M.D., University of Pittsburgh
- Brian Haab, Ph.D., Van Andel Research Institute

12:00 p.m. – 1:30 p.m.

Lunch (On Your Own)

1:30 p.m. – 2:00 p.m.
Palm A/D

Discussion on Unblinding, Return of Biomarker Data on Reference Sets, and Other Issues Raised by the DMCC

- Ziding Feng, Ph.D., The University of Texas MD Anderson Cancer Center
- Margaret Pepe, Ph.D., Fred Hutchinson Cancer Research Center
- Mark Thornquist, Ph.D., Fred Hutchinson Cancer Research Center

2:00 p.m. – 3:20 p.m.
Palm A/D

Patenting Biomarkers
Session Moderator: Sharmistha Ghosh-Janjigian, Ph.D., National Cancer Institute

2:00 p.m. – 2:20 p.m.

Diagnostic and Biomarker Patent Strategies
Lisa A. Haile, J.D., Ph.D., DLA Piper LLP (US)

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Tuesday March 7, 2017 (Continued)

Patenting Biomarkers (Continued)

2:20 p.m. – 2:40 p.m.
Palm A/D

Ex Vivo Protein Oxidation as a Metric of Plasma/Serum Integrity
Chad Borges, Ph.D., Arizona State University

2:40 p.m. – 3:20 p.m.

Panel Discussion

- Josh LaBaer, M.D., Ph.D., Arizona State University
- Lisa A. Haile, J.D., Ph.D., DLA Piper LLP (US)
- Chad Borges, Ph.D., Arizona State University
- Surinder Batra, Ph.D., University of Nebraska
- Daniel Chan, Ph.D., Johns Hopkins University
- Sandy Markowitz, M.D., Ph.D., Case Western Reserve University
- Kyle Siegal, J.D., Arizona State University

3:20 p.m. – 3:40 p.m.

Break

3:40 p.m. – 5:30 p.m.
Palm A/D

Developing CLIA and FDA Approved Biomarkers
Session Moderator: Paul Wagner, Ph.D., National Cancer Institute

3:40 p.m. – 4:00 p.m.

Airway mRNA Biomarker for Lung Cancer Detection
Avrum Spira, M.D., Boston University

4:00 p.m. – 4:20 p.m.

MiPS (Mi Prostate Score Urine test)
Scott Tomlins, Ph.D., University of Michigan

4:20 p.m. – 4:40 p.m.

Risk of Ovarian Cancer (ROMA)
Steven Skates, Ph.D., Massachusetts General Hospital

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Tuesday March 7, 2017 (Continued)

Developing CLIA and FDA Approved Biomarkers (Continued)

4:40 p.m. – 5:00 p.m.
Palm A/D

DCP and AFP-L3 Biomarkers for Liver Cancer
Hiro Yamada, Ph.D., Wako Diagnostics

5:00 p.m. – 5:30 p.m.

Panel Discussion

- Daniel Chan, Ph.D., Johns Hopkins University
- Arul Chinnaiyan, M.D., Ph.D., University of Michigan
- Scott Tomlins, Ph.D., University of Michigan
- Avrum Spira, M.D., Boston University
- Steven Skates, Ph.D., Massachusetts General
- Hiro Yamada, Ph.D., Wako Diagnostics
- David Reese, Ph.D., Provista Diagnostics

5:30 p.m.

Adjourn for the Day

7:00 p.m. – 9:00 p.m.
Palm A/D

Data Sharing and Informatics Subcommittee Meeting

Wednesday March 8, 2017

7:00 a.m. – 8:00 a.m.
Palm Ballroom Foyer

Sign-in and Continental Breakfast

8:00 a.m. – 8:10 a.m.
Palm A/D

Charge to Collaborative Groups
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:10 a.m. – 12:00 p.m.

Collaborative Group Meetings (By Invitation Only)

8:10 a.m. – 10:00 a.m.

Scientific Discussions

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Wednesday March 8, 2017 Continued

Collaborative Group Meetings: Scientific Discussions Continued

Xavier Room

Breast and Gynecological Cancers

- Steven Skates, Ph.D., Massachusetts General Hospital
- Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center
- Christos Patriotis, Ph.D., National Cancer Institute

Palm A/D

Gastrointestinal Cancers

- Brian Haab, Ph.D., Van Andel Research Institute
- Robert Schoen, M.D., M.P.H., University of Pittsburgh
- Jo Ann Rinaudo, Ph.D., National Cancer Institute
- Matthew Young, Ph.D., National Cancer Institute

Joshua Tree Room

Lung and Upper Aerodigestive Cancers

- Pierre Massion, M.D., Vanderbilt -Ingram Cancer Center
- Harvey Pass, M.D., New York University School of Medicine
- Lynn Sorbara, Ph.D., National Cancer Institute
- Karl Krueger, Ph.D., National Cancer Institute

Augustine Room

Prostate and Urological Cancers

- Martin Sanda, M.D., Emory University
- John Semmes, Ph.D., Eastern Virginia Medical School
- Jacob Kagan, Ph.D., M.S.c., National Cancer Institute
- Richard Mazurchuk, Ph.D., National Cancer Institute

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Wednesday March 8, 2017 Continued

10:00 a.m. – 12:00 p.m. Evaluation and Prioritization (Closed Session Limited to EDRN Members)

Collaborative Groups will finalize proposals for the use of Set-aside Funds and large validation studies that require Core Funds. Each Collaborative Group will also analyze ongoing validation projects, evaluate their scientific relevance in light current diagnostic needs, and prioritize these projects.

1. 10 minutes for each ongoing and pending Team Projects and Validation Studies
2. Following presentations, the Collaborative Group will discuss these projects/studies for scientific merits and decide whether to continue them.
3. Prepare a report on these projects and to be presented to the entire Steering Committee with recommendation to close out or continue these projects/studies. Steering Committee vote may be required.

12:00 p.m. – 1:30 p.m. Lunch (On Your Own)

12:00 p.m. – 1:30 p.m. EDRN Executive Committee Meeting (Closed Session)
Palm E

1:30 p.m. – 4:50 p.m. Reports from Collaborative Groups on Status of Team Projects and Potential Projects
Palm A/D
Session Moderator: Christos Patriotis, Ph.D., National Cancer Institute

1:30 p.m. – 2:00 p.m. Breast Cancer
Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

2:00 p.m. – 2:30 p.m. Ovarian Cancer
Steven Skates, Ph.D., Massachusetts General Hospital

2:30 p.m. – 3:00 p.m. Colon and Esophageal Cancers
Robert Schoen, M.D., M.P.H., University of Pittsburgh

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Wednesday March 8, 2017 Continued

Reports from Collaborative Groups on Status of Team Projects and Potential Projects

3:00 p.m. – 3:20 p.m.

Break

3:20 p.m. – 3:50 p.m.
Palm A/D

Pancreatic Cancer
Brian Haab, Ph.D., Van Andel Research Institute

3:50 p.m. – 4:20 p.m.

Lung Cancer

- Pierre Massion M.D., Vanderbilt -Ingram Cancer Center
- Harvey Pass, M.D., New York University School of Medicine

4:20 p.m. – 4:50 p.m.

Prostate Cancer
Martin Sanda, M.D., Emory University

4:50 p.m.

Adjourn for the Day

Thursday March 9, 2017

7:00 a.m. – 8:00 a.m.
Palm Ballroom Foyer

Sign-in and Continental Breakfast

8:00 a.m. – 9:20 a.m.
Palm A/D

Proteomic Platforms: Unique platforms that might be of Use to Others
Session Moderator: Jacob Kagan, Ph.D., National Cancer Institute

8:00 a.m. – 8:20 a.m.

Systematic Development of Prostate Cancer Liquid Biopsies: Proteomics and Proteogenomics of Post-DRE Urines and Cancer Tissues
Thomas Kislinger, Ph.D., University of Toronto University Health Network

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Thursday March 9, 2017 Continued

**Proteomic Platforms: Unique platforms that might be of Use to Others
Continued**

8:20 a.m. – 8:40 a.m.
Palm A/D

Approaches for Use of Patient-derived Xenografts
in Biomarker Discovery
Michael Lewis, Ph.D., Baylor College of Medicine

8:40 a.m. – 9:00 a.m.

High-density Antibody Arrays as Proteomic,
Glycomic and Autoantibody Discovery Tools
Paul Lampe, Ph.D., Fred Hutchinson Cancer
Research Center

9:00 a.m. – 9:20 a.m.

Integrating HuProt Array PTM Activity Profiling
with MS Proteomic Analysis for
Biomarker/Target Discovery
Zhen Zhang, Ph.D., Johns Hopkins University

9:20 a.m. – 9:40 a.m.
Palm Ballroom Foyer

Break

9:40 a.m. – 11:00 a.m.
Palm A/D

**Genomics Platforms: Platforms that Might be
of Use to Others**
Session Moderator: Lynn Sorbara, Ph.D.,
National Cancer Institute

9:40 a.m. – 10:00 a.m.

Methylome Analysis using Methylation Arrays:
Application to Gastrointestinal Cancers
William Grady, M.D., Fred Hutchinson Cancer
Research Center

10:00 a.m. – 10:20 a.m.

Ultrasensitive Detection of Tumor Specific
Methylation Changes for the Early Detection of
Lung Cancer
James Herman, M.D., University of Pittsburgh

31st EDRN Steering Committee Meeting
Biomarkers at the Crossroads
March 7-9, 2017
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Thursday March 9, 2017 Continued

Genomics Platforms: Platforms that Might be of Use to Others Continued

10:20 a.m. – 10:40 a.m.
Palm A/D

Early Detection of NSCLC: PBMC to PAXgene/Microarrays to Nanostring
Louise Showe, Ph.D., Wister Institute

10:40 a.m. – 11:00 a.m.

Targeted DNA and RNA Sequencing to Understand Cancer Development and Detection
Scott Tomlins, Ph.D., University of Michigan

11:00 a.m. – 11:10 a.m.
Palm A/D

Final Remarks

- Joshua LaBaer, M.D., Ph.D., Arizona State University
- Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

11:10 a.m.

Adjourn